Telomir Pharmaceuticals, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Total operating expenses were $3,942,048.
Profit Margin
| 2023 | 0 | -13.07M |
|---|
TELO Income Statement (2023 – 2023)
| 2023 | |
|---|---|
Revenue | |
Revenue | 0 |
Cost of revenue | 3.94M |
Gross profit | -3.94M |
Operating exp. | |
Research and development | 1.57M |
Selling and marketing | 0 |
Total operating expenses | 3.94M |
Operating income | -3.94M |
Other income (expenses), net | -9.12M |
Income before tax | -13.07M |
Income tax expense | 0 |
Net income | -13.07M |
Earnings per share | |
Basic EPS | -0.44 |
Diluted EPS | -0.44 |
| Data source |